This study investigates advanced or metastatic urothelial cancer and other solid tumors. The purpose of this study is to evaluate the investigational medication in these conditions.
This study evaluates the safety, tolerability, and effectiveness of the investigational medication. It focuses on how the medication interacts with certain cancer cells.
- Who can participate: Participants must be adults with advanced or metastatic solid tumors, such as urothelial carcinoma or triple negative breast cancer. They must have received prior systemic therapy or have no standard therapy available.
- Study details: Participants will receive an investigational medication, which is being tested for its effects on cancer.
- Study timelines: The study will last up to 4 years.
How understandable was the trial content above?
Hard to understand
Easy to understand